Bayer posts 45 percent gain in quarterly earnings
Bayer said 13,400 plaintiffs were seeking damages, alleging that use of the company's glyphosate-based weedkillers caused their cancer, up from 11,200 in January.
FRANKFURT: German drug and farming supplies company Bayer posted a 45 per cent gain in quarterly core earnings thanks to the acquisition of seed maker Monsanto, while the legal burden it took on with the deal increased.
Adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 4.19 billion euros ($4.67 billion), it said on Thursday, edging past the 4.12 billion euro average analyst forecast in a Reuters poll.
Read Also: Bayer signs deal with adivo to develop antibodies for veterinary medicine
The company said 13,400 plaintiffs were seeking damages, alleging that use of the company's glyphosate-based weedkillers caused their cancer, up from 11,200 in January.
The company is still aiming for an increase in 2019 EBITDA before special items to about 12.2 billion euros, excluding the effect of currency swings and the planned sale of assets such as the animal health unit.
Read Also: Glyphosate Case: Bayer to comply with court mediation order
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd